Nls pharmaceutics to participate in the oppenheimer sleep disorders summit: deep dive into narcolepsy and idiopathic hypersomnia

Zurich, switzerland / accesswire / november 27, 2023 / nls pharmaceutics ltd. (nasdaq:nlsp, nlspw) ("nls" or the "company"), a swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that alex zwyer, chief executive officer of nls pharmaceutics, will present at the oppenheimer sleep disorders summit: deep dive into narcolepsy and idiopathic hypersomnia, hosted by francois brisebois, managing director, senior research biotechnology analyst, in new york on friday, december 1, 2023 at 10:30 am est.
NLSP Ratings Summary
NLSP Quant Ranking